Latest Conference Articles

November 13th 2016, 6:27am

AASLD Liver Meeting

The use of immunotherapy as a treatment for cancer is progressively increasing with a flood of recent approvals for immune checkpoint inhibitors directed against CTLA-4 and PD-1.

November 13th 2016, 5:21am

AASLD Liver Meeting

Hepatocellular carcinoma‎ incidence continues to rise among patients with hepatitis B despite improvements in antiviral therapies, stressing the importance of screening and surveillance in this population.

November 13th 2016, 4:55am

AASLD Liver Meeting

​George N. Ioannou, MD, associate professor, VA Puget Sound Health Care System, University of Washington School of Medicine, discusses a study evaluating the effectiveness of direct antiviral agents for hepatitis C virus patients with hepatocellular carcinoma (HCC).

November 13th 2016, 4:36am

SITC Meeting

Pembrolizumab monotherapy reduced the risk of death by 27% compared with chemotherapy for patients with advanced urothelial carcinoma whose disease progressed after prior treatment.

November 13th 2016, 4:22am

SITC Meeting

The combination of lirilumab and nivolumab resulted in an objective response rate of 24.1% in patients with squamous cell carcinoma of the head and neck.

November 13th 2016, 3:41am

PER® New York Lung Cancer Symposium

Individualizing frontline therapy for patients with non–small cell lung cancer based on preferences and clinical experience, as well as efficacy and safety data from pivotal trials, is an appropriate method for selecting EGFR-targeted agents.

November 13th 2016, 3:28am

PER® New York Lung Cancer Symposium

The treatment landscape for patients with ALK-rearranged non–small cell lung cancer is changing rapidly, gearing up the potential for more therapeutic options to address the heterogeneity of the mechanism of resistance in this population.

November 13th 2016, 3:20am

PER® New York Lung Cancer Symposium

Roman Perez-Soler, MD, chairman of the Department of Oncology and chief of the Division of Medical Oncology at Montefiore Medical Center, Albert Einstein College of Medicine of Yeshiva University, discusses the impact of osimertinib (Tagrisso) on patients with T790M-positive non–small cell lung cancer (NSCLC).

November 13th 2016, 3:03am

PER® New York Lung Cancer Symposium

Anne Chiang, MD, PhD, professor and thoracic oncologist at Yale Cancer Center, discusses molecular testing in lung cancer and how it affects treatment decisions.

November 13th 2016, 1:31am

AASLD Liver Meeting

Efforts are under way to further evaluate the effects of regorafenib on sorafenib-resistant HCC cells, including the role of suppressing the ERK signaling pathway.

November 13th 2016, 1:16am

SITC Meeting

Joaquim Bellmunt, MD, PhD, attending physician of Solid Tumor Oncology at Dana-Farber Cancer Institute, discusses findings from the phase III KEYNOTE-045 study, which compared second- or third-line pembrolizumab with investigator-choice chemotherapy as a treatment for patients with metastatic or locally advanced, unresectable urothelial carcinoma.

November 13th 2016, 12:26am

AASLD Liver Meeting

Stevan A. Gonzalez, MD MS, clinical assistant professor, department of internal medicine, Texas A&M College of Medicine, medical director of liver transplantation, Simmons Transplant Institute, Baylor All Saints Medical Center, discusses a cost effectiveness analysis of treating hepatitis C patients with hepatocellular carcinoma (HCC) before or after a liver transplant.

November 12th 2016, 7:06pm

PER® New York Lung Cancer Symposium

Lung cancer treatment has undergone a game-changing transformation within the past few years, with a burst of FDA approvals of targeted agents and immunotherapies across a number of indications.

November 10th 2016, 5:20am

SMR Congress

Rodabe N. Amaria, MD, assistant professor Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the results of a recent trial testing neoadjuvant and adjuvant dabrafenib plus trametinib versus standard of care in high-risk resectable BRAF-mutant melanoma.

November 10th 2016, 3:06am

SMR Congress

Results from a safety, tolerability, and dose escalation phase Ib/II study involving intratumoral SD-101 and pembrolizumab (Keytruda) have demonstrated that the combination was well-tolerated with no dose-limiting toxicities.

November 10th 2016, 2:48am

SMR Congress

Treatment with the combination of dabrafenib and trametinib before and after surgery demonstrated a dramatic improvement in relapse-free survival compared with the standard of care for patients with stage IIIb/c or oligometastatic BRAF-mutant melanoma.

November 10th 2016, 2:22am

SMR Congress

Keith T. Flaherty, MD, director of the Termeer Center for Targeted Therapy, Massachusetts General Hospital and professor of Medicine, Harvard Medical School, discusses the results from the COLUMBUS trial, testing encorafenib plus binimetinib compared to vemurafenib or encorafenib as single agents.

November 10th 2016, 1:53am

SMR Congress

Bin Zheng, PhD, assistant professor of Dermatology at Harvard Medical School and assistant biologist at Massachusetts General Hospital, discusses the potential for phenformin, a drug created for Type 2 diabetes, to be used for patients with melanoma.

November 9th 2016, 8:10pm

SMR Congress

The combination of the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib reduced the risk of progression or death by 46% compared with vemurafenib (Zelboraf) for patients with BRAF-mutant unresectable melanoma.

November 9th 2016, 5:18am

SMR Congress

The combination of nilotinib and trametinib proved to be synergistic in BRAF/NRAS wild-type melanoma.